Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

  • Price (GBX)904.00
  • Today's Change-14.00 / -1.53%
  • Shares traded132.43k
  • 1 Year change23.50%
  • Beta0.4609
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
Total returns on £1000
1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)+30.31%
NAVInternational Biotechnology Trust (Ordinary Share)+24.74%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Announcements

More ▼

Key statistics

On Friday, International Biotechnology Trust (IBT:LSE) closed at 904.00, -9.65% below its 52-week high of 1,000.50, set on Dec 15, 2025.
52-week range
Today
480.00Apr 09 20251,000.50Dec 15 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding31.90m
Market cap292.87m GBP
Total assets325.52m GBP
Total expense ratio--
High914.00
Low874.00
Previous close918.00
Average volume78.93k
YTD Change-6.22%
Beta0.4609
Diluted NAV (est)982.00
Diluted NAV (last pub)969.84
Premium/Discount-7.94%
Net Gearing+1.54%
Annual div (ADY)31.81 GBX
Annual div yield (ADY)3.52%
Div ex-dateDec 29 2025
Div pay-dateJan 23 2026
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.